ADAPTIVE BIOTECHNOLOGIES CORPORATION Operating Lease, Expense
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Operating Lease, Expense of $9.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-02-26
- ADAPTIVE BIOTECHNOLOGIES CORPORATION operating lease, expense for the quarter ending 2021-12-31 was $3.10M, a 72.22% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION operating lease, expense for the quarter ending 2021-09-30 was $3.10M, a 121.43% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION operating lease, expense for the quarter ending 2021-06-30 was $3.10M, a 158.33% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION operating lease, expense for the quarter ending 2021-03-31 was $3.10M, a 181.82% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION operating lease, expense for fiscal 2025 was $9.20M, a 4.17% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION operating lease, expense for fiscal 2024 was $9.60M, a 15.79% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION operating lease, expense for fiscal 2023 was $11.40M, a 8.06% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION operating lease, expense for fiscal 2022 was $12.40M, a 0.00% change from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $9.20M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $9.60M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $11.40M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $12.40M 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $6.20M derived: sum of 2 quarters · filed 2024-02-29 | $9.30M derived: sum of 3 quarters · filed 2024-02-29 | $12.40M 10-K · filed 2024-02-29 |
| 2021-09-30 | $3.10M 10-Q · filed 2021-11-03 | $6.20M derived: sum of 2 quarters · filed 2021-11-03 | $9.30M 10-Q · filed 2021-11-03 | $11.10M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $3.10M 10-Q · filed 2021-08-04 | $6.20M 10-Q · filed 2021-08-04 | $8.00M derived: sum of 3 quarters · filed 2023-02-14 | $9.40M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $3.10M 10-Q · filed 2021-05-05 | $4.90M derived: sum of 2 quarters · filed 2023-02-14 | $6.30M derived: sum of 3 quarters · filed 2023-02-14 | $7.50M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $3.20M derived: sum of 2 quarters · filed 2023-02-14 | $4.40M derived: sum of 3 quarters · filed 2023-02-14 | $5.50M 10-K · filed 2023-02-14 |
| 2020-09-30 | $1.40M 10-Q · filed 2021-11-03 | $2.60M derived: sum of 2 quarters · filed 2021-11-03 | $3.70M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $1.20M 10-Q · filed 2021-08-04 | $2.30M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $1.10M 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |